FSTL-1 Antagonists Modulate Inflammatory Cytokines
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory conditions, including autoimmune diseases and cancer, are inadequate in modulating the proinflammatory effects of Follistatin-like Protein-1 (FSTL-1), which contributes to increased expression of cytokines like TNF-α, IL-6, and IL-17, exacerbating conditions such as arthritis and cancer progression.
Innovation Solution
Development of antagonists, such as neutralizing antibodies, small molecules, soluble FSTL-1 receptors, antisense RNA, and RNAi, that bind to FSTL-1 to modulate its activity, reducing proinflammatory effects and inhibiting the induction of Th17 cells, thereby addressing the inflammatory response in autoimmune diseases and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If FSTL-1 is used to treat inflammatory conditions, then anti-proliferative effects are achieved, but proinflammatory effects (increased cytokine expression) worsen the condition
Solution Approach 1:
The patent applies local quality by developing antagonists with specific binding characteristics to FSTL-1 that selectively block proinflammatory effects while preserving anti-proliferative effects. Different antagonist types (neutralizing antibodies, small molecules, soluble receptors) are designed to interact with specific domains or conformations of FSTL-1, achieving localized modulation of its dual functional effects in different cellular contexts.
Solution Approach 2:
The patent employs parameter changes by modifying the molecular structure and binding properties of antagonists to alter FSTL-1 activity parameters. By changing the binding affinity, specificity, and stoichiometry of antagonist-FSTL-1 interactions, the patent achieves differential control over FSTL-1's biological effects, suppressing harmful proinflammatory cytokine expression while maintaining beneficial anti-proliferative activity.
2Object-generated harmful factors
If neutralizing antibodies are developed to block FSTL-1, then proinflammatory effects are reduced, but manufacturing complexity increases
Solution Approach 1:
The patent applies universality by developing a platform approach to FSTL-1 antagonists where a single antibody design can target multiple proinflammatory pathways mediated by FSTL-1. The neutralizing antibodies are engineered to bind conserved epitopes on FSTL-1 that are critical for its proinflammatory function across different disease contexts, allowing one antagonist to address multiple harmful effects rather than requiring separate agents for each indication.
Solution Approach 2:
The patent employs copying by creating simplified versions or analogs of natural FSTL-1 binding proteins. Soluble FSTL-1 receptors and engineered antibody fragments are designed as copycat molecules that replicate the binding specificity of endogenous proteins but with enhanced stability, reduced immunogenicity, and improved manufacturability compared to full-length antibodies.
3Reliability
If FSTL-1 antagonists are used in autoimmune diseases, then disease severity decreases, but Th17 cell induction may be affected
Solution Approach 1:
The patent applies the intermediary principle by using FSTL-1 antagonists as mediator molecules that indirectly regulate Th17 cell induction rather than directly targeting T cells. The antagonists bind to FSTL-1, preventing it from interacting with its cellular receptors and downstream signaling pathways that would otherwise promote Th17 differentiation. This indirect mechanism allows modulation of Th17 responses as a downstream effect of blocking FSTL-1's broader proinflammatory actions.
Data Source
AI summary
Follistatin-like protein (FSTL-1) is a secreted glycoprotein of unknown function, first isolated from mouse osteoblastic cells as a transforming growth factor-β1-inducible gene. The inventors have discovered that FSTL-1 is a proinflammatory mediator. As such, the invention provides for composition and methods of using agents that bind to FSTL-1 to modulate various types of inflammation (e.g., autoimmune diseases). Inhibitors and antagonists of FSTL-1, particularly antibodies or antibody fragments, may be used to treat conditions related to inflammation, such as arthritis. In addition, the inventors have discovered that FSTL-1 has a role in the Th17 pathway. Accordingly, the invention provides for compositions and methods of using agents which bind to FSTL-1 to modulate the generation of Th17 cells. Such agents are useful for delaying development of and treating diseases associated with undesired production of Th17 cells, such as autoimmune diseases. Furthermore, since FSTL-1 is a proinflammatory mediator with a role in cancer, the invention provides for compositions and methods of using a pharmaceutical composition of FSTL-1 to delay development of or treat cancer.